User profiles for G. Riely
 | Gregory J. Riely, MD, PhDMemorial Sloan Kettering Cancer Center Verified email at MSKCC.org Cited by 95189 |
[HTML][HTML] International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of …
Introduction: Adenocarcinoma is the most common histologic type of lung cancer. To
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …
Non–small cell lung cancer
…, JD Patel, KM Pisters, K Reckamp, GJ Riely… - Journal of the national …, 2010 - jnccn.org
Lung cancer is the leading cause of cancer-related death in the United States. An estimated
219,440 new cases (116,090 men; 103,350 women) of lung and bronchus cancer were …
219,440 new cases (116,090 men; 103,350 women) of lung and bronchus cancer were …
Systemic therapy for locally advanced and metastatic non–small cell lung cancer: a review
KC Arbour, GJ Riely - Jama, 2019 - jamanetwork.com
… Dr Riely reported receiving grants and nonfinancial support from Pfizer, Roche/Genentech/Chugai,
Novartis, Merck, and Takeda; having US patent 20170273982A1 pending for an …
Novartis, Merck, and Takeda; having US patent 20170273982A1 pending for an …
[HTML][HTML] Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
Background Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors
gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations …
gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations …
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers,
but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor …
but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor …
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Tumor molecular profiling is a fundamental component of precision oncology, enabling the
identification of genomic alterations in genes and pathways that can be targeted …
identification of genomic alterations in genes and pathways that can be targeted …
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Purpose: All patients with EGF receptor (EGFR)–mutant lung cancers eventually develop
acquired resistance to EGFR tyrosine kinase inhibitors (TKI). Smaller series have identified …
acquired resistance to EGFR tyrosine kinase inhibitors (TKI). Smaller series have identified …
[HTML][HTML] Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
…, DR Camidge, T Mok, V Hirsh, GJ Riely… - … England Journal of …, 2013 - Mass Medical Soc
Background In single-group studies, chromosomal rearrangements of the anaplastic lymphoma
kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an …
kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an …
Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology
… KRAS is a G-protein with GTPase activity that is part of the MAP/ERK pathway; point
mutations in KRAS most commonly occur at codon 12. Data suggest that approximately 25% of …
mutations in KRAS most commonly occur at codon 12. Data suggest that approximately 25% of …
[HTML][HTML] Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Background Chromosomal rearrangements of the gene encoding ROS1 proto-oncogene
receptor tyrosine kinase (ROS1) define a distinct molecular subgroup of non–small-cell lung …
receptor tyrosine kinase (ROS1) define a distinct molecular subgroup of non–small-cell lung …